ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

SoCal EPAP Nasal Therapy Device for Sleep Apnea: Bongo Rx Availability Expanded

Southern California Pulmonary and Sleep Disorders Medical Center announced the expanded availability of Bongo Rx, an FDA-cleared nasal therapy device designed to help treat mild to moderate obstructive sleep apnea.

-- The Southern California Pulmonary and Sleep Disorders Medical Center announced expanded access to Bongo Rx therapy, a reusable nasal device designed to support individuals diagnosed with obstructive sleep apnea who are seeking an alternative to traditional CPAP therapy. The compact device is designed to help support nighttime breathing and improve sleep quality using a simple, non-powered approach.

People interested in learning more about sleep apnea testing and treatment options can explore additional information at https://sleepmd4u.com/bongo-sleep-apnea-therapy-device/

The therapy was recently introduced as part of a broader effort to expand accessible solutions for people living with sleep apnea. According to the American Academy of Sleep Medicine, an estimated 30 million adults in the United States are affected by sleep apnea, yet many cases remain undiagnosed.

Bongo Rx therapy uses soft nasal inserts that create gentle resistance during exhalation, a mechanism known as expiratory positive airway pressure (EPAP). This resistance helps support the airway during sleep without requiring electricity, hoses, or a bedside machine.

Unlike traditional CPAP devices, Bongo Rx is small, lightweight, and designed to fit directly into the nostrils. Because the device is compact and portable, it can be used during travel and may appeal to individuals who prefer a simpler treatment approach.

The therapy is typically prescribed after sleep apnea testing confirms the condition. Once prescribed, patients receive a set of reusable nasal devices designed for nightly use, with different sizes available to ensure a comfortable fit.

Healthcare professionals increasingly recognize the importance of offering multiple treatment approaches for sleep apnea. While CPAP therapy remains a widely used option, alternative devices such as EPAP-based solutions provide additional choices for individuals exploring ways to support their breathing during sleep.

By expanding access to therapies like Bongo Rx, Thousand Oaks-based Southern California Pulmonary and Sleep Disorders Medical Center aims to provide more flexible care pathways for individuals evaluating sleep apnea treatment after diagnosis. These options may help people address sleep disruptions while maintaining comfort and convenience.

Individuals interested in learning more about sleep apnea testing and treatment options can visit https://sleepmd4u.com/

Contact Info:
Name: Ronald A. Popper, MD, FCCP, FAASM, DABSM
Email: Send Email
Organization: Southern California Pulmonary and Sleep Disorders Medical Center
Address: 317 S. Moorpark Road, Thousand Oaks, CA 91361, United States
Website: https://sleepmd4u.com

Source: PressCable

Release ID: 89186583

In case of identifying any problems, concerns, or inaccuracies in the content shared in this press release, or if a press release needs to be taken down, we urge you to notify us immediately by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will be readily accessible to address your concerns and take swift action within 8 hours to rectify any issues identified or assist with the removal process. We are committed to delivering high-quality content and ensuring accuracy for our valued readers.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  210.14
+4.77 (2.32%)
AAPL  251.49
+3.50 (1.41%)
AMD  202.68
+1.35 (0.67%)
BAC  47.52
+0.36 (0.76%)
GOOG  299.02
+0.23 (0.08%)
META  604.06
+10.40 (1.75%)
MSFT  383.00
+1.13 (0.30%)
NVDA  175.64
+2.94 (1.70%)
ORCL  154.34
+4.66 (3.11%)
TSLA  380.85
+12.89 (3.50%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.